How Common Is HSV-2? Global and U.S. Prevalence

Roughly one in eight people worldwide between the ages of 15 and 49 carries herpes simplex virus type 2, and the number has been climbing. Global estimates for 2020 put the count at about 520 million people, or 13.3% of that age group, with around 26 million new infections each year. In the United States, the picture has shifted over the past few decades, but HSV-2 remains one of the most common sexually transmitted infections in the country. The numbers vary dramatically by region, sex, and race, and the majority of infected people have never been diagnosed.

Global Prevalence and Regional Differences

The World Health Organization has funded successive rounds of modeling to track HSV-2 worldwide. The most recent global estimates, based on 2020 data, found 519.5 million people aged 15 to 49 living with the virus, translating to a prevalence of 13.3%. That same year saw roughly 25.6 million new infections.¹ An earlier round of estimates using 2016 data had put the prevalent count at about 491.5 million, or 13.2%, so the overall global picture has been relatively stable in percentage terms even as absolute numbers rise with population growth.²

Those averages hide enormous regional variation. The WHO African Region has by far the highest prevalence, estimated at around 37% in recent modeling.³ A large systematic review of sub-Saharan Africa specifically confirmed that figure, noting it was several times the rate seen in Europe or the Western Pacific.⁴ The Region of the Americas comes next at about 17%, followed by Europe at roughly 11%, the Western Pacific at about 9%, the Eastern Mediterranean near 7%, and South-East Asia at around 7%.³ Since 1980, prevalence has been inching upward in Africa, Europe, and the Eastern Mediterranean while declining in other regions, meaning the global gap is widening rather than closing.

Research coverage itself is uneven. A review of two decades of HSV-2 studies in low- and middle-income countries found that East Asia, South Asia, and East Africa had the most published research, while the Middle East, North Africa, and Western Asia had essentially none.⁵ That gap means the global estimates for some regions rest on thin data, and true prevalence in understudied areas could be higher or lower than the models suggest.

Prevalence in the United States

The U.S. has tracked HSV-2 through the National Health and Nutrition Examination Survey (NHANES) for decades, giving an unusually clear picture of how prevalence has changed over time. Between 1988 and 1994, about 22% of Americans aged 12 and older tested positive for HSV-2 antibodies, representing roughly 45 million people.⁶ That was a significant jump from earlier surveys in the late 1970s, and it raised alarm at the time.

Since that peak, U.S. prevalence has declined. By the 2005-2008 NHANES cycle, overall seroprevalence among people aged 14 to 49 had fallen to about 16%.⁷ More recent NHANES data have continued that downward trend, with estimates in the low-to-mid teens. The reasons for the decline are not entirely clear, but changes in sexual behavior, increased condom use, and broader awareness of sexually transmitted infections are all likely contributors. Even so, millions of Americans carry the virus, and incident cases continue each year.

Who Is Most Affected

HSV-2 prevalence is not evenly distributed across the population. In the U.S., sex and race are the two strongest demographic predictors.

Women carry HSV-2 at roughly double the rate of men. In the 1999-2004 NHANES data, seroprevalence was about 23% among women and 11% among men.⁸ The 2005-2008 round showed a similar gap, with women at about 21% and men lower.⁷ This difference is largely biological: the genital mucosa in women presents a larger surface area vulnerable to infection during sexual contact, making female-to-male transmission somewhat less efficient than male-to-female transmission.

Racial disparities are even starker. Among non-Hispanic Black Americans, HSV-2 seroprevalence has consistently been around 39% to 40% in national surveys, compared to roughly 12% to 15% among non-Hispanic white Americans.⁷ That disparity is not explained by differences in individual sexual behavior. It reflects the way sexually transmitted infections circulate within sexual networks: because partnerships tend to form within racial and ethnic communities, higher baseline prevalence in a network means higher exposure risk for each individual within it, creating a self-reinforcing cycle. On top of that, Black Americans who carry HSV-2 are more likely to be undiagnosed; after adjusting for other factors, they had about twice the odds of being unaware of their infection compared to white Americans.⁹

How Prevalence Builds with Age

Unlike many sexually transmitted infections that peak in young adulthood and decline with treatment, HSV-2 is a lifelong infection. Once you acquire it, it stays. That means prevalence accumulates with age as more people in each birth cohort become infected over time. A person who tests negative at 20 can test positive at 35; nothing about the earlier test protects against later acquisition.

A New Zealand birth-cohort study that followed people to age 38 illustrated this clearly. By that age, about 27% of women and 17% of men had been seropositive for HSV-2 at some point. Infection rates peaked for women between ages 21 and 26 and for men between 26 and 32, then dropped sharply for both sexes after 32.¹⁰ In U.S. data, people who are unmarried or not living with a partner tend to have higher prevalence at older ages, likely reflecting ongoing exposure through new partnerships over many years.¹¹ The takeaway is that HSV-2 is not primarily a young person’s infection in terms of who is carrying it, even though new infections are most common among younger adults.

Most People Don’t Know They Have It

One of the defining features of HSV-2 is how often it goes unrecognized. Estimates vary, but the majority of people with HSV-2 have never received a clinical diagnosis. Many have mild or atypical symptoms they attribute to something else, and some never have noticeable symptoms at all. A high proportion of undiagnosed infections is one of the key factors driving ongoing transmission.¹²

Even people who have never had a recognized outbreak shed virus intermittently from genital skin. A study that collected daily genital swabs from HSV-2-seropositive people found that about 72% of those who reported no history of genital herpes were nonetheless shedding virus on some days.¹³ The rate of subclinical shedding in people who had never noticed symptoms was comparable to the rate in people who had a known history of outbreaks. A larger study confirmed that while symptomatic people shed slightly more often, the amount of virus present during subclinical shedding episodes was similar regardless of symptom history.¹⁴ This matters because it means the virus can be transmitted by partners who genuinely do not know they carry it.

Why the U.S. Does Not Routinely Screen for HSV-2

Given that most infections are undiagnosed, you might wonder why doctors do not just test everyone. The U.S. Preventive Services Task Force has repeatedly recommended against routine serologic screening in asymptomatic adults, and the reason comes down to the performance of available blood tests. The most widely used commercial assay, HerpeSelect, has high sensitivity (it catches about 99% of truly positive people) but variable specificity, meaning it also flags a meaningful number of people who do not actually have the virus. Pooled estimates put the specificity at around 81% at the manufacturer’s recommended cutoff, but individual studies ranged from as low as 41% to as high as 98%.¹⁵

In a general population where most people are truly negative, even a modest false-positive rate produces a lot of incorrect diagnoses. A person told they have genital herpes when they actually don’t may experience unnecessary distress, relationship conflict, and stigma. Raising the cutoff value on the test improves specificity to about 89% but sacrifices some sensitivity.¹⁵ The task force concluded that the harms of widespread screening, including anxiety from false positives and the lack of evidence that screening asymptomatic people improves health outcomes, outweigh the benefits. Testing is still recommended when someone has symptoms or a known exposure, but blanket screening of the general population is not standard practice.

HSV-1 Is Changing the Genital Herpes Picture

When people think of genital herpes, they typically think of HSV-2, but the landscape is shifting. HSV-1, traditionally associated with oral cold sores, has become a growing cause of genital infections, especially in high-income countries. In parts of North America and Western Europe, HSV-1 has actually overtaken HSV-2 as the leading cause of first-episode genital herpes, particularly among adolescents and young adults.¹⁶

This shift is partly a consequence of declining rates of oral HSV-1 infection in childhood. When fewer children are exposed to HSV-1 through non-sexual contact, they enter adolescence without antibodies that would offer partial cross-protection against genital HSV-1 infection. A six-year study at a medical center in Kentucky documented the trend as it was emerging, finding that by 1999, HSV-1 accounted for about 32% of genital herpes cases in men and 45% in women at that facility.¹⁷ This has practical implications: genital HSV-1 tends to cause fewer recurrences than genital HSV-2, so people with HSV-1 genital infections generally have a less symptomatic course over time. But it also complicates public messaging, because the old division of “HSV-1 is oral, HSV-2 is genital” no longer holds reliably.

Condoms, Antivirals, and Reducing Transmission

Because HSV-2 spreads through skin-to-skin contact and can be transmitted from areas not covered by a condom, there has long been uncertainty about how much condoms help. The evidence says they do, though not as completely as for infections transmitted strictly through fluids. A pooled analysis of multiple prospective studies found that people who used condoms 100% of the time had about a 30% lower risk of acquiring HSV-2 compared to people who never used them.¹⁸ A case-crossover analysis that looked at individual sex acts supported this, finding that each unprotected act slightly increased the odds of acquisition while protected acts did not.¹⁹

One trial specifically looked at male-to-female transmission and found that condom use more than 25% of the time was associated with a much larger protective effect for women, reducing their risk by about 75% compared to less frequent use.²⁰ The same study did not find a significant protective effect for men acquiring HSV-2 from women, though the analysis was limited by small numbers. The pooled analysis, with more data, found no gender difference in condom effectiveness, suggesting the single-study result for men may have been a fluke of sample size.

Daily antiviral medication offers another layer of protection. In a large randomized trial, when the HSV-2-positive partner in a discordant couple took daily valacyclovir, the rate of transmission to the uninfected partner was cut roughly in half, from about 3.6% to 1.9% over eight months. Symptomatic infections in particular dropped by about 75%.²¹ Combining suppressive antivirals with consistent condom use gives the best available protection short of abstinence with an infected partner, though neither alone nor together do they eliminate the risk entirely.

The Connection Between HSV-2 and HIV

HSV-2 and HIV have a synergistic relationship that has significant public health implications, particularly in sub-Saharan Africa where both infections are highly prevalent. HSV-2 infection increases the risk of acquiring HIV by roughly threefold: a longitudinal study in South Africa found that when either partner had HSV-2, the risk of female-to-male HIV transmission was about three times higher.²² The relationship goes both ways: HIV infection in either partner also roughly doubled the risk of HSV-2 transmission. The biological explanation involves HSV-2 recruiting specific immune cells to genital tissue, and those same cells happen to be HIV’s preferred targets.²³

A study of an urban U.S. population demonstrated the overlap in concrete terms, finding that HSV-2 prevalence was strongly associated with HIV prevalence at the community level, with an odds ratio above three.²⁴ Some researchers have estimated that a substantial fraction of new HIV infections in high-prevalence settings would not occur if HSV-2 were eliminated, making herpes control part of the broader HIV prevention conversation.

Neonatal Herpes and Pregnancy

One of the most serious consequences of HSV-2 involves transmission from mother to baby during delivery. Neonatal herpes is rare but can be devastating, causing serious neurological damage or death. The risk is highest when a mother acquires a new genital herpes infection late in pregnancy, because she has not yet developed antibodies that would pass to the baby and help protect it.²⁵

Counterintuitively, a large U.S. study found that neonatal herpes rates were actually higher among babies born to women who were seronegative for both HSV types (54 per 100,000 live births) than among babies born to women already seropositive for HSV-2 (22 per 100,000). The likely explanation is that seronegative women who acquire a new infection near delivery pose the greatest risk, while women with longstanding HSV-2 have partial immunity that limits viral shedding and provides some passive antibody protection to the infant.²⁶ An interesting wrinkle: maternal genital HSV-1 was associated with considerably higher odds of neonatal infection than maternal genital HSV-2 in a pooled analysis, possibly because HSV-1 genital infections tend to produce more aggressive first episodes in adults who acquire them later in life.²⁷

The Psychological Weight of a Diagnosis

For an infection that causes mild or no physical symptoms in most people, the emotional fallout of an HSV-2 diagnosis can be disproportionately heavy. Genital herpes carries a cultural stigma that far outweighs its medical seriousness for the average person. Research on the psychology of herpes stigma describes a feedback loop: negative feelings about being infected lead to poor coping, which in turn may increase the frequency of outbreaks, which reinforces the stigmatized identity and the negative feelings.²⁸

Disclosure to sexual partners is a major source of anxiety. A study of people with chronic genital herpes found that herpes-related stigma was directly associated with not telling partners about a diagnosis, and about a third of participants had clinically significant anxiety.²⁹ In a study of women specifically, perceived stigma, along with coping style and social support, accounted for about two-thirds of the variation in quality-of-life scores, a finding that underscores how much of the disease burden is psychological rather than physical.³⁰ The irony is that the stigma discourages disclosure, and lack of disclosure likely increases transmission, perpetuating the very problem that generates the stigma.

The Economic Toll and the Elusive Vaccine

The global economic burden of HSV-2 is substantial, though quantifying it depends heavily on assumptions about how much psychological distress infected people experience. One modeling study estimated that genital herpes caused by HSV-2 was responsible for the loss of about 62 million quality-adjusted life years globally in 2019 under the assumption that all infected people were aware of their status. If only those who were symptomatic were counted as affected, the number dropped to about 6 million. The estimated economic value of those losses ranged from about $22 billion to $212 billion, depending on the assumption about awareness.³¹ That tenfold range illustrates the difficulty of costing a disease whose main burden for many carriers is psychological: if you don’t know you have it, it may cost you nothing in quality of life.

Despite the enormous number of people affected, there is still no approved vaccine for HSV-2. Multiple candidates have looked promising in animal models only to fail in human trials. The most high-profile disappointment was a glycoprotein D2 subunit vaccine that showed efficacy in some subgroups during early trials but produced null results in a larger study. Researchers have argued that the failure means the field needs to fundamentally rethink its approach to HSV vaccine design rather than iterate on the same strategy.³² Several newer candidates using different approaches are in preclinical or early clinical stages, but a widely available vaccine remains years away at best. Given that HSV-2 has been infecting humans for an estimated 1.6 million years, having jumped to an ancestor of modern humans from the ancestor of chimpanzees, the virus has had a very long time to evolve strategies for evading our immune response.³³ That deep evolutionary history helps explain why building effective immunity through vaccination has proven so difficult.